TCGA-64-1677-01A-01R-0946-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 77
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.450
- MYC_TARGETS_V1+0.400
- INTERFERON_GAMMA_RESPONSE+0.320
- ALLOGRAFT_REJECTION+0.300
- E2F_TARGETS+0.270
- DNA_REPAIR+0.260
- INTERFERON_ALPHA_RESPONSE+0.240
- MYC_TARGETS_V2+0.240
- PANCREAS_BETA_CELLS+0.150
- CHOLESTEROL_HOMEOSTASIS+0.140
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.510
- MITOTIC_SPINDLE-0.480
- WNT_BETA_CATENIN_SIGNALING-0.440
- UV_RESPONSE_DN-0.430
- TGF_BETA_SIGNALING-0.380
- APICAL_JUNCTION-0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.340
- NOTCH_SIGNALING-0.330
- PROTEIN_SECRETION-0.310
- MYOGENESIS-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-D8-A1Y3-01A-11R-A157-07 | — | B | 0.842 |
| 2 | AUR-AFUK-TTM1-A-1-0-R-A743-41 | — | B | 0.834 |
| 3 | TCGA-66-2771-01A-01R-0980-07 | — | cohortSQ1 | 0.832 |
| 4 | TCGA-D8-A1XL-01A-11R-A14M-07 | — | B | 0.821 |
| 5 | TCGA-37-4132-01A-01R-1100-07 | — | cohortA3 | 0.819 |
| 6 | TCGA-TN-A7HL-01A-11R-A34R-07 | — | — | 0.810 |
| 7 | MBCProject_3717_T2_RNA | — | B | 0.805 |
| 8 | TCGA-37-4130-01A-01R-1100-07 | — | cohortA1 | 0.790 |
| 9 | TCGA-58-8387-01A-11R-2296-07 | — | cohortSQ2 | 0.787 |
| 10 | bd9c63e1-a1cb-4b2f-a909-839ce2fd8618 | — | — | 0.781 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.450 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.320 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.270 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.260 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.240 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.240 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.150 | Cobimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.140 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.120 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.110 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.090 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.070 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.030 | Idelalisib | — uncovered |
| COMPLEMENT | 0.020 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.020 | Inavolisib | — uncovered |